E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
A. Keith Stewart
Consultant or Advisory Role - Celgene
Susanna J. Jacobus
No relevant relationships to disclose
Rafael Fonseca
Consultant or Advisory Role - Amgen; Binding Site; Bristol-Myers Squibb; Celgene; Genzyme; Lilly; Medtronic; Millennium; Onyx; Otsuka
Research Funding - Celgene; Onyx
Matthias Weiss
No relevant relationships to disclose
Natalie Scott Callander
No relevant relationships to disclose
Asher Alban Akmal Chanan-Khan
No relevant relationships to disclose
Vincent Rajkumar
No relevant relationships to disclose